Does Orforglipron Cause Depression or Mood Changes?

No, it isn’t established that orforglipron (Foundayo) causes depression. But like other GLP-1 receptor agonists, its labeling directs patients and prescribers to watch for new or worsening depression, unusual changes in mood or behavior, or suicidal thoughts, and to get medical attention if they show up. That’s a monitoring precaution applied across the drug class — not proof the drug causes these symptoms. Here’s what that means in practice, who should be extra cautious, and what to actually watch for.

What “monitor for mood changes” actually means

Orforglipron is a GLP-1 receptor agonist, and this drug class — across oral and injectable forms — carries labeling language advising patients and prescribers to be alert for new or worsening depression, anxiety, agitation, or other unusual changes in mood or behavior during treatment, along with any thoughts of suicide or self-harm. This is consistent with mood-related precautions found across GLP-1 receptor agonist labeling generally, including semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), per their MedlinePlus drug information.

It’s important to be precise about what this instruction is and isn’t. It is a directive to pay attention and report symptoms promptly. It is not a confirmed causal finding that orforglipron, or GLP-1 drugs generally, cause depression or suicidal thoughts in people who take them. Regulatory monitoring for a drug class can lead to precautionary labeling well before — or even without — a confirmed causal relationship being established.

Why this precaution exists at all

Mood-related monitoring language on GLP-1 labels reflects ongoing post-marketing safety surveillance of this drug class as a whole, not a signal isolated to any one medication. When a new drug in an established class — like orforglipron joining the GLP-1 receptor agonist category — comes to market, it typically inherits the class’s standard precautionary labeling and monitoring guidance, even before its own long-term, real-world safety data has accumulated. That’s a reasonable, cautious approach for a relatively new medication, and it’s the same approach that applied to earlier GLP-1 drugs when they were newer to the market.

If you’re also weighing orforglipron against an antidepressant you already take, Does Orforglipron Interact With Antidepressants? covers the separate question of drug-drug interaction via delayed gastric emptying — a different issue from the mood-monitoring precaution discussed here.

Who should be especially cautious

If you have a personal or family history of depression, anxiety, suicidal thoughts, or suicide attempts, tell your prescriber before starting orforglipron. That history doesn’t automatically rule the medication out, but it’s exactly the kind of information your prescriber needs to weigh the precaution against your specific situation and to plan appropriate monitoring — something only they can do with your full medical picture in view.

If you’re currently in mental health treatment, keep that clinician informed you’re starting a GLP-1 medication too, so both prescribers have the full picture.

Symptoms worth reporting

Across GLP-1 receptor agonist labeling, the categories of symptoms worth watching for and reporting promptly include:

Symptom category	Examples
Mood changes	New or worsening sadness, hopelessness, loss of interest in things you usually enjoy
Anxiety or agitation	New or worsening nervousness, restlessness, irritability
Behavior changes	Acting differently than usual, withdrawing from people or activities
Suicidal thoughts or self-harm	Any thoughts of suicide or hurting yourself — this warrants immediate medical attention

If you or someone close to you notices any of these while you’re taking orforglipron, contact your prescriber. If there’s any thought of suicide or self-harm, treat it as urgent and seek immediate medical attention rather than waiting for a scheduled appointment.

Separating the drug from everything else going on

Starting a weight-management medication often coincides with other changes — different eating patterns, new exercise habits, appetite suppression, and sometimes significant weight loss over a relatively short period. Any of those changes can affect mood and emotional wellbeing on their own, independent of the medication’s direct pharmacology. That overlap is part of why it can be genuinely hard to tell whether a mood change is related to the drug, the broader lifestyle shift, or something unrelated entirely.

That ambiguity isn’t a reason to dismiss a mood change — it’s a reason to bring it up. Your prescriber can help sort out what’s likely contributing and whether any change in your treatment plan makes sense.

How this compares across GLP-1 medications

	Orforglipron (Foundayo)	Semaglutide (Ozempic, Wegovy, Rybelsus)	Tirzepatide (Mounjaro, Zepbound)
Drug class	GLP-1 receptor agonist	GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
Mood/behavior monitoring precaution	Yes, class-wide	Yes, per MedlinePlus	Yes, per MedlinePlus
Confirmed causal link to depression	Not established	Not established	Not established
What to do if symptoms occur	Contact prescriber promptly; treat suicidal thoughts as urgent	Same	Same

The pattern is consistent across the class: a precaution to monitor and report, not a confirmed cause-and-effect finding for any single drug in the category.

What this article won’t do

It won’t tell you that orforglipron is safe for you if you have a history of depression or suicidal thoughts, and it won’t tell you it isn’t. That’s an individualized clinical judgment your prescriber makes with your full history in view. It also won’t attach a number — a percentage, a rate, an odds ratio — to the likelihood of experiencing a mood-related symptom on orforglipron, because no verified figure exists that this article can responsibly attribute to a specific source. If you want that kind of quantified risk information, ask your prescriber, who can discuss it in the context of your own risk factors.

Bottom line

It isn’t established that orforglipron causes depression. What is true is that orforglipron, like other GLP-1 receptor agonists, comes with a precaution to monitor for new or worsening depression, mood or behavior changes, and suicidal thoughts, and to seek help promptly if they appear. If you have a personal or family history of depression or suicidal thoughts, tell your prescriber before starting — and if you or someone close to you notices concerning mood changes at any point during treatment, don’t wait to bring it up. This is educational information, not medical advice or a mental health resource; if you’re having thoughts of suicide or self-harm, contact a healthcare provider or emergency services right away.

For more on orforglipron’s broader safety profile, see Orforglipron Side Effects, and for who the medication is generally intended for, Who Should Take Orforglipron.